FindMyKOL
Clinical trialNCT00362817CompletedPhase 1/2Interventional

Carboplatin and Temozolomide (Temodar) for Recurrent and Symptomatic Residual Brain Metastases

NCT00362817 is a phase 1/2 interventional trial sponsored by Ohio State University Comprehensive Cancer Center. As of 21 Nov 2026, it is completed. It studies Carboplatin and Temozolomide in Brain Metastases and Brain Tumor. The registry lists an enrollment of 17 participants at 1 site in 1 country. The registry lists a start date of 31 Oct 2004 and a primary completion date of 31 Jan 2008.

View the registry record on ClinicalTrials.gov

Key facts

Registry attributes as recorded on the ClinicalTrials.gov study record.

Key facts for NCT00362817
FieldValue
Registry IDNCT00362817
StatusCompleted
PhasePhase 1/2
Study typeInterventional trial
Lead sponsorOhio State University Comprehensive Cancer Center
Enrollment17
Registered sites1
Countries1
ConditionsBrain Metastases and Brain Tumor
DrugsCarboplatin and Temozolomide
Start31 Oct 2004
Primary completion31 Jan 2008
Study completion29 Feb 2008
Last update posted1 Jun 2017

Registered summary

The lay summary the sponsor registered on ClinicalTrials.gov.

Purpose: The primary objective of this study is to determine if chemotherapy with carboplatin and temozolomide significantly affects the response rates, or size of disease, in patients with brain metastases, originating from cancer in other parts of the body, compared to patients who have already been treated with radiation. Survival, causes of death, recurrence of disease in the central nervous system, toxicity, and quality of life will all be measured as secondary objective in this study.

Investigators

The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

1 registered facility, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

Ohio, United States1 site
  • Ohio State University

    Columbus

United States, by state

AlaskaAKMaineMEVermontVTNew HampshireNHWashingtonWAMontanaMTNorth DakotaNDMinnesotaMNWisconsinWIMichiganMINew YorkNYMassachusettsMARhode IslandRIOregonORIdahoIDSouth DakotaSDIowaIAIllinoisILIndianaINOhio: 1 siteOH1PennsylvaniaPANew JerseyNJConnecticutCTCaliforniaCANevadaNVWyomingWYNebraskaNEMissouriMOKentuckyKYWest VirginiaWVVirginiaVAMarylandMDDelawareDEArizonaAZUtahUTColoradoCOKansasKSArkansasARTennesseeTNNorth CarolinaNCSouth CarolinaSCNew MexicoNMOklahomaOKLouisianaLAMississippiMSAlabamaALGeorgiaGAHawaiiHITexasTXFloridaFLDistrict of ColumbiaDC
Fewer sitesMore sites

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Questions about NCT00362817

Each answer restates registry values shown on this page.

What is NCT00362817?

NCT00362817 is a phase 1/2 interventional trial sponsored by Ohio State University Comprehensive Cancer Center. It studies Carboplatin and Temozolomide in Brain Metastases and Brain Tumor.

Who leads NCT00362817?

The registry names Herbert Newton, MD (principal investigator, Ohio State University) as the overall official.

Where does NCT00362817 run?

The registry lists 1 site in 1 country. Every site with a stated country is in one country: United States.

Which drugs does NCT00362817 study?

The registered drug and biological interventions are Carboplatin and Temozolomide.

When did NCT00362817 end?

The registry lists a primary completion date of 31 Jan 2008 and a study completion date of 29 Feb 2008. The sponsor last updated the record on 1 Jun 2017.

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 21 Nov 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.